Literature DB >> 15004204

HLA-DQ8-associated T cell responses to the diabetes autoantigen phogrin (IA-2 beta) in human prediabetes.

Katalin Kelemen1, Peter A Gottlieb, Amy L Putnam, Howard W Davidson, Dale R Wegmann, John C Hutton.   

Abstract

Susceptibility to type 1A autoimmune diabetes is linked to expression of particular MHC class II molecules, notably HLA-DQ8 in man and the orthologous I-Ag7 in the nonobese diabetic mouse. In the present study, we analyzed two peptide epitopes (peptides 2 and 7) from the diabetes autoantigen phogrin (IA-2beta), in the context of their presentation by the I-Ag7 and HLA-DQ8 molecules and their role as potential T cell antigenic epitopes in human diabetes. Both of these peptides are targets of diabetogenic CD4+ T cell clones in the nonobese diabetic mouse. Transgenic mice expressing HLA-DQ8 as the sole class II molecule generated a robust T cell-proliferative response when primed with peptide 2 or peptide 7 in CFA. Analysis of the IL-2 secretion from peptide 2-reactive T cell hybridomas stimulated with alanine-substituted peptides identified three residues that were crucial to the response. Among 41 islet cell Ag-positive prediabetic human subjects, 36.5% showed PBMC-proliferative responses to peptide 7, 17.1% to peptide 2, and 17.1% to both peptides; no response was seen among 20 matched healthy controls. Stratification of the data based upon HLA haplotype suggested that peptide 7 could be presented by at least one HLA-DR molecule in addition to HLA-DQ8, a finding that was supported by blocking studies with monomorphic mAbs. The results indicate that common phogrin peptides are targeted by autoreactive T cells in human and murine type 1A diabetes, and that the responses may in part be associated with the similar peptide-binding specificities of I-Ag7 and HLA-DQ8.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15004204     DOI: 10.4049/jimmunol.172.6.3955

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Type 1 diabetes-associated HLA-DQ8 transdimer accommodates a unique peptide repertoire.

Authors:  Menno van Lummel; Peter A van Veelen; Arnaud Zaldumbide; Arnoud de Ru; George M C Janssen; Antonis K Moustakas; George K Papadopoulos; Jan W Drijfhout; Bart O Roep; Frits Koning
Journal:  J Biol Chem       Date:  2011-12-19       Impact factor: 5.157

2.  Natural peptides selected by diabetogenic DQ8 and murine I-A(g7) molecules show common sequence specificity.

Authors:  Anish Suri; James J Walters; Michael L Gross; Emil R Unanue
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

3.  An update on the use of NOD mice to study autoimmune (Type 1) diabetes.

Authors:  Rodolfo José Chaparro; Teresa P Dilorenzo
Journal:  Expert Rev Clin Immunol       Date:  2010-11       Impact factor: 4.473

4.  Telomere dysfunction, autoimmunity and aging.

Authors:  Philipp J Hohensinner; Jörg J Goronzy; Cornelia M Weyand
Journal:  Aging Dis       Date:  2011-12-02       Impact factor: 6.745

Review 5.  Novel diabetes autoantibodies and prediction of type 1 diabetes.

Authors:  Janet M Wenzlau; John C Hutton
Journal:  Curr Diab Rep       Date:  2013-10       Impact factor: 4.810

6.  Mapping I-A(g7) restricted epitopes in murine G6PC2.

Authors:  Tao Yang; Anita C Hohenstein; Catherine E Lee; John C Hutton; Howard W Davidson
Journal:  Immunol Res       Date:  2013-03       Impact factor: 2.829

Review 7.  T cell recognition of autoantigens in human type 1 diabetes: clinical perspectives.

Authors:  Roberto Mallone; Vedran Brezar; Christian Boitard
Journal:  Clin Dev Immunol       Date:  2011-07-19

Review 8.  T Cell-Mediated Beta Cell Destruction: Autoimmunity and Alloimmunity in the Context of Type 1 Diabetes.

Authors:  Adam L Burrack; Tijana Martinov; Brian T Fife
Journal:  Front Endocrinol (Lausanne)       Date:  2017-12-05       Impact factor: 5.555

9.  Tolerogenic vaccination reduced effector memory CD4 T cells and induced effector memory Treg cells for type I diabetes treatment.

Authors:  Jingyao Zhang; Wenjuan Gao; Xu Yang; Jingjing Kang; Yongliang Zhang; Qirui Guo; Yanxin Hu; Guoliang Xia; Youmin Kang
Journal:  PLoS One       Date:  2013-07-19       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.